Introduction
Fragile X Syndrome (FXS) is caused by the expansion of a CGG triplet repeat in the 5' untranslated region of the FMR1 gene which induces silencing of gene expression and the absence of the mRNA-binding protein Fragile X Mental Retardation Protein (FMRP). The "mGluR Theory of Fragile X" (Bear et al., 2004) postulates that, in the absence of FMRP, protein translation downstream of Group I metabotropic glutamate receptors (mGluRs) is abnormal, leading to enhanced mGluR signaling which contributes to many of the phenotypes associated with FXS. The mGluR theory also suggests that reducing Group I mGluR (mGluR1 and mGluR5) signaling should alleviate some of the symptoms of FXS (Bear, 2005) . Indeed, treatment with mGluR5 antagonists has been shown to reduce seizures and hyperactivity in FMR1 KO mice (Yan et al., 2005) , restore dendritic spine defects in cultured neurons lacking FMRP (de Vrij et al., 2008) and correct behavioral deficits in FMR1 null flies (McBride et al., 2005) . Genetic reduction of mGluR5 expression in mice also rescues several FXS phenotypes including abnormal ocular dominance plasticity, increased protein synthesis, seizures and spine defects (Dolen et al., 2007) .
While much focus has been placed on Group I mGluRs, evidence for changes in the GABAergic system in FXS has emerged, and both Group I mGluR antagonists and GABA B receptor agonists are being tested in clinical trials of FXS (see Hampson et al., 2011 for a review). GABA exerts its effects through two distinct families of receptors. The ionotropic GABA A receptors are pentameric chloride channels that mediate fast inhibition through controlling the movement of chloride across the cell membrane, while metabotropic GABA B receptors are heteromeric G-protein coupled receptors that require dimerization of the R1 and R2 subunits in order to form fully functional receptors. GABA B receptors are localized pre-or postsynaptically where they mediate slow inhibition through G i α -mediated inhibition of adenylyl cyclase and/or activation of inwardly-rectifying K+ channels (GIRKs). Presynaptic GABA B receptors also regulate the release of glutamate (Vigot et al., 2006) .
Decreased GABA A receptor expression and function has been demonstrated in FMR1 knockout mice (El Idrissi et al., 2005; D'Hulst et al., 2006; Curia et al., 2009; D'Hulst et al., 2009; Adusei et al., 2010; Olmos-Serrano et al., 2010) . We have also recently demonstrated that GABA B R1 expression is down-regulated in the forebrains of immature and mature FMR1 mice compared to wild-type mice . This observation is particularly interesting because GABA B receptor expression has also been reported to be reduced in the brains of persons with autism, a disorder related to FXS (Fatemi et al., 2009) . However, other studies conducted on FMR1 mice showed increased sensitivity to the locomotor suppressing effects of the orthosteric GABA B receptor agonist R/S-baclofen (Zupan and Toth, 2008) , and treatment with R-baclofen prevents audiogenic seizures in these mice (Pacey et al., 2009) . Additionally, increased GABA B R signaling is at least partially responsible for the rescue of audiogenic seizures in FMR1 mice lacking Regulator of G-protein Signaling 4 (RGS4, a protein that normally inhibits GABA B R signaling; Pacey et al., 2009; Pacey et al., 2011) . Finally, drugs that increase GABA signaling rescued diet-induced glutamate lethality in FMR1 null flies (Chang et al., 2008) . Taken together, these findings point to the GABAergic system as a promising pharmacological target for treating FXS.
The purpose of the present study was three-fold. The first goal was to investigate the effectiveness of a combination of MPEP and R-baclofen at low doses that did not block seizures in FMR1 mice when given individually. The second objective was to examine both receptor This article has not been copyedited and formatted. The final version may differ from this version.
6:00 p.m. Seizure activity was observed and scored using a seizure severity score as follows:
Wild running = 1; clonic seizure = 2; tonic seizure = 3; status epilepticus/respiratory arrest/death = 4 (Musumeci et al., 2000) . For the data analyses the animals that obtained a score of 0 or 1 were classified as "no seizures" while animals with a score of 2 or more were considered as having seizures. Seizure incidence for drug injected animals was compared to the appropriate vehicle and Fisher's Exact test was used for statistical analysis of seizure susceptibility incidence.
For drug injection studies, an intraperitoneal (i.p.) or subcutaneous (s.c.) injection of drug or vehicle (0.1mL/10g body weight) was administered 60 minutes prior to seizure testing diphenyl-1H-pyrazol-5-yl) benzamide; Tocris Bioscience) suspended in 50% DMSO/ 50% sterile saline.
Western blotting
Immediately after seizure testing, mice were euthanized with an overdose of ketamine/xylazine and the brains removed and frozen on dry ice. Quantitative western blotting was performed on whole forebrain homogenates as previously described (Adusei et al., 2010) .
The following antibodies were used: mouse anti-GABA B R1 (clone NR3A/49; 1:250;
NeuroMab, University of California, Davis/NIH), mouse anti-GABA B R2 (clone N81/2; 1:750;
NeuroMab, University of California, Davis/NIH), rabbit anti-mGluR5 (1:500; Chemicon) and mouse anti-GAPDH antibody (1:40,000-1:100,000; Sigma) and a goat anti-mouse (Jackson Labs) or goat anti-rabbit (Pierce) HRP-conjugated secondary antibody. The immunoreactive proteins were visualized using the FluorChem TM MultiImage Light Cabinet (Alpha Innotech).
Densitometric analysis was carried out using the AlphaEaseFC software (Alpha Innotech). The intensity of the band of interest was normalized relative to the GAPDH band intensity. Protein expression in drug treated animals is presented as a percentage of expression in vehicle controls.
An unpaired student t test was used to determine statistical significance.
Results

Acute administration of MPEP, R-baclofen or GS-39783 reduced seizures in FMR1 mice
FMR1 knockout mice are susceptible to audiogenic seizures (Chen and Toth, 2001 ).
Since the incidence of audiogenic seizures is very low (~5%) in wild-type C57BL/6 mice (Pacey et al., 2009) , only FMR1 knockout mice were used in this study. Single injections of MPEP (Yan et al., 2005) and R-baclofen (Pacey et al., 2009 ) have been previously shown to reduce the incidence of audiogenic seizures in FMR1 mice. To confirm these results, FMR1 mice were treated with 30 mg/kg MPEP or 1mg/kg R-baclofen 60 minutes before seizure testing (Fig. 1A) .
Vehicle treated FMR1 mice had a seizure incidence of 60%. Both 30mg/kg MPEP and 1 mg/kg R-baclofen significantly reduced seizure incidence to 13% (p = 0.03 compared to vehicle). The GABA B receptor positive allosteric modulator GS-39783 was also tested for its anti-seizure capabilities. GS-39783 (30 mg/kg) reduced seizures in FMR1 mice to 25% compared to vehicle controls (10% PEG/15% DMSO/75% saline), which had a seizure rate of 69%, although this difference did not quite reach statistical significance (Fig. 1A , p = 0.054).
FMR1 mice develop tolerance to R-baclofen and GS-39783 but not MPEP after repeated administration
Next we determined whether these drugs could maintain their anti-convulsant activities after subchronic administration. FMR1 mice were injected with MPEP (30 mg/kg), R-baclofen (1 mg/kg), GS39783 (30 mg/kg), or vehicle daily for 6 days beginning on postnatal day (PND) 25.
Seizure testing was carried out 60 minutes after the final injection on PND30. After subchronic administration, 82% of vehicle treated mice had seizures (note that the seizure incidence in the vehicle group was consistently higher after subchronic administration as compared to a single injection), while none of the eight animals treated with 30 mg/kg MPEP had seizures (p = 0.0007, Fig. 1B ). This indicated that MPEP retained its anticonvulsant activity after sub-chronic administration. In contrast, the anticonvulsant efficacy of R-baclofen and GS-39783 was reduced after subchronic administration compared with single drug injections (Fig. 1B) , with 50% and 38% of animals exhibiting seizures respectively, compared to controls after 6 daily injections (p = 0.32 and 0.18 respectively compared to vehicle).
Acute administration of a combination of low dose MPEP and R-baclofen prevents seizures in FMR1 KO mice
This article has not been copyedited and formatted. The final version may differ from this version. mice, we postulated that treating mice with combined low doses of MPEP and R-baclofen should also reduce seizures and that using low doses of both drugs might prevent the tolerance seen with the high dose of R-baclofen. Treatment with 10 mg/kg MPEP alone or 0.5 mg/kg R-baclofen alone did not significantly affect the incidence of audiogenic seizures compared to vehicle controls (67% seizures for MPEP or R-baclofen alone; 60% seizures for vehicle; Fig. 2A ).
However, when animals were treated simultaneously with a combined dose of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen the incidence of seizures dropped to 17% (p = 0.03 compared to vehicle). This finding demonstrates that low doses of MPEP and R-baclofen that are not anticonvulsant when administered alone, can significantly reduce seizure activity when administered in combination. This finding supports the theory that an imbalance in mGluR and GABA B receptor signaling contributes to audiogenic seizures in FMR1 null mice.
FMR1 mice develop tolerance to combined low dose MPEP plus R-baclofen after repeated administration
We also tested whether the combination of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen maintained its anticonvulsant activity after repeated administrations ( Figure 2B ). Similar to a single injection, 6 daily injections of either 10 mg/kg MPEP or 0.5 mg/kg R-baclofen alone did not affect seizure incidence with 89% and 78% of animals exhibiting seizures respectively, + 3.6%; p < 0.001; Fig 3A) . An analysis of R-baclofen and GS-39783 treated animals was performed to determine whether GABA B receptor expression might correlate with seizure incidence. However, there was no significant difference in GABA B R1 or R2 expression in the brains of mice that had seizures compared to those that did not have seizures after treatment with either R-baclofen or GS-39783 (data not shown).
mGluR5 and GABA B receptor expression was also examined in the forebrains of mice treated subchronically with low dose MPEP (10 mg/kg) and R-baclofen (0.5 mg/kg) alone and in combination. Western blot analysis demonstrated no difference in GABA B receptor expression after treatment with low dose R-baclofen ( Fig. 4C and D A lower dose of CDPPB (10 mg/kg) administered alone had no effect on seizure incidence (43% seizure incidence; p = 0.44 compared to vehicle), while 10 mg/kg CDPPB administered with 1 mg/kg R-baclofen significantly reduced the incidence of seizures (0%) compared to vehicle (p = 0.02; Fig. 5B ).
We were intrigued by the finding that a high dose of the mGluR5 positive allosteric modulator CDPPB blocked seizures in FMR1 KO mice when administered acutely. To determine whether this effect persisted after repeated administrations, we treated FMR1 mice for six days with 30 mg/kg CDPPB and tested for seizures one hour after the final dose. After subchronic treatment, 63% of the mice had seizures, which was not different from vehicle (83% seizure incidence; p = 0.58, Figure 
In a final series of experiments, mice were treated for 5 days (PND25-29) with low doses of MPEP (10 mg/kg) or R-baclofen (0.5 mg/kg), alone or in combination, followed by a single high dose of MPEP (30 mg/kg) 1 hour before testing on PND30. In mice pre-treated with only the low dose MPEP, a single high dose of MPEP still blocked seizures (0% seizure incidence vs.
88% in vehicle-treated; p = 0.005; Fig. 7) . Surprisingly, when mice were pre-treated with a combination of low dose MPEP plus low dose R-baclofen for 5 days, a single injection of 30 mg/kg MPEP was no longer effective in preventing seizures (86% seizure incidence; p = 1.00 vs.
vehicle). Moreover, pre-treatment for 5 days with low dose R-baclofen alone also produced tolerance to the anti-seizure effects of high dose MPEP (57% seizure incidence; p = 0.28 vs.
vehicle). These results indicate that subchronic treatment with a low dose of R-baclofen can modulate the response to MPEP suggesting cross-talk between the GABA B and mGluR5
pathways.
Discussion
Our results show that when administered as single doses, MPEP (30 mg/kg), R-baclofen (1 mg/kg) and the GABA B positive modulator GS-39783 (30 mg/kg) displayed robust suppression of audiogenic seizures in FMR1 mice. However, when FMR1 mice were treated daily for 6 days, MPEP retained its anti-convulsant activity while R-baclofen and GS-39783 did not.
Baclofen has previously been shown to induce tolerance in several models of chronic pain (Lehmann et al., 2003; Sands et al., 2003) and in humans after intrathecal infusion (Akman et al., 1993; Nielsen et al., 2002) . In the present study, western blot analysis showed no significant difference in GABA B receptor expression in the forebrains of FMR1 mice after subchronic treatment with R-baclofen. This is consistent with previous findings suggesting that baclofen induces tolerance through mechanisms other than down-regulation of GABA B receptor expression (Lehmann et al., 2003; Sands et al., 2003) . However, it is possible that microdissection and analysis of specific brain regions (e.g. the inferior colliculus, a brain region that may mediate audiogenic seizures) might have demonstrated regional changes in GABA B receptor expression after baclofen injection.
We initially hypothesized that targeting GABA B receptors with GS-39783, a positive allosteric modulator, rather than an orthosteric agonist (R-baclofen), might provide a better longterm approach given the overall theoretical advantages of using allosteric modulators as therapeutic drugs (Keov et al., 2011; Gregory et al., 2011) , and the specific observations that GS-39783 has been shown to produce fewer side effects and less tolerance after repeated administration in mouse models of anxiety. In addition,
Gjoni and Urwyler (2008) demonstrated that prolonged administration of GS-39783 did not lead
to GABA B receptor desensitization in cultured cells. However, in the present study, GS-39783 produced tolerance in FMR1 mice, with an accompanying decrease in GABA B receptor levels.
The differences between our results examining the effects of GS-39783 on seizures in FMR1 mice and those of Mombereau et al., (2004) who studied the effects of this drug in tests of anxiety and depression in GABA B R1 null mice may be due to differences in the strain of mice Our data also demonstrate that R-baclofen promotes tolerance to the anti-convulsant effects of MPEP in FMR1 mice. High dose MPEP on day 6 of treatment retained anti-convulsant efficacy in mice that had been pretreated for 5 days with low dose MPEP. However, tolerance ensued when low dose MPEP was administered together with low dose R-baclofen over the same 5 day period. Even more surprising was that pre-treatment of the mice with low dose R-baclofen alone for 5 days also induced tolerance to the anti-seizures effects of MPEP given on day 6. Similar to the hypothesis above, if R-baclofen-induced GABA B receptor desensitization leads to increased presynaptic glutamate release, the high dose of MPEP used here might not provide sufficient mGluR5 blockade to prevent seizures.
Another intriguing possibility is that the intracellular signaling pathways of both receptors may converge to promote drug tolerance. Group I mGluRs are coupled to Gαq and the activation of phospholipase C and release of intracellular Ca 2+ via the IP 3 receptor. The GABA B receptor is coupled to Gαi/Gαo G-proteins inducing activation of potassium channels and the inhibition of adenylyl cyclase. Rives et al., 2009 studied cross-talk between these two pathways and reported that stimulation of the GABA B receptor strongly potentiates signaling of Gαq coupled mGluR1, most likely via the activation of phospholipase C from the βγ G-proteins subunits generated from complexes with Gαi/Gαo after GABA B receptor stimulation.
Interestingly, this effect was only observed when the mGluR and GABA B were activated simultaneously, and the mGluR1 potentiation was larger after lower levels of mGluR1 activation compared to higher levels of mGluR1 activation. We propose that the low dose of MPEP used here (Fig. 7) , allowed residual signaling through mGluR5 with release of intracellular Ca Since group I mGluR signaling is enhanced in FMR1 mice we were surprised to find that treatment with a high dose (30 mg/kg) of the mGluR5 positive allosteric modulator CDPPB alone did not exacerbate seizures as predicted, but rather completely prevented audiogenic seizures in FMR1 mice. This anticonvulsant effect appeared to be dose-dependent as 10 mg/kg CDPPB had no effect on seizure activity. Uslaner et al. (2009) reported an inverted U-shaped dose-response effect whereby improved memory recognition and markers of synaptic plasticity were seen in rats treated with low doses of CDPPB and this effect was lost at the higher dose.
One potential explanation for the observation that CDPPB blocked seizures at high doses in FMR1 mice is that mGluR5 receptor desensitization occurred at the high drug concentration thereby effectively decreasing mGluR5 signaling and reducing audiogenic seizure susceptibility.
However, this is unlikely given that tolerance to the anti-seizure effects of high dose CDPPB developed after subchronic administration despite a reduction in mGluR5 expression (Fig. 6 ).
Another possibility is that the pharmacological actions of CDPPB may convert from a positive modulator at low concentrations to a negative allosteric modulator at high concentrations.
CDPPB has been shown to potentiate glutamate stimulation of mGluR5 at very low concentrations with an EC 50 = 27 nM (Kinney et al., 2005) . Moreover, CDPPB binds to the same site as MPEP in the transmembrane region of mGluR5 (Chen et al., 2007; Rodriguez et al., 2010) . We obtained support for this idea by examining the effects of CDPPB on mGluR5 positive allosteric modulators of mGluR5 are being developed for use as novel anti-psychotics (Gasparini et al., 2008; Uslaner et al., 2009; Rodriguez et al., 2010) .
There is presently no cure for FXS and current therapies are aimed at treating specific symptoms such as anxiety and hyperactivity. Recent advances in understanding the pathobiology of FXS have led to new and exciting drug targets with the potential to treat the disease itself, rather than individual symptoms (see Levenga et al., 2010 and Hampson et al., 2011 for reviews). Based on these findings, clinical trials are underway examining the use of several mGluR5 negative modulators and the GABA B agonist Arbaclofen in treating FXS (www.clinicaltrials.gov). Taken together, the results of our study indicate that in FMR1 mice tolerance develops rapidly to the anti-convulsant effects of R-baclofen, even at very low doses.
In addition, cross-tolerance to MPEP occurred after repeated administration of R-baclofen.
These results indicate that caution is warranted and that future pre-clinical drug studies should evaluate the effectiveness of long term drug administration. mg/kg MPEP or 0.5 mg/kg R-baclofen had no effect on seizure incidence in FMR1 mice.
Authorship Contributions
Participated in research design
However, when administered in combination, the drugs significantly reduced the incidence of seizures. B, when administered daily for 6 days, 10 mg/kg MPEP or 0.5 mg/kg R-baclofen alone did not block seizures. A combination of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen also failed to alleviate seizures after subchronic treatment. This article has not been copyedited and formatted. The final version may differ from this version. 
